Replaces Prod. #: ALX-340-054
High affinity selective agonist for the cannbinoid CB1 receptor (Ki= 2.2 nM; CB2 receptor Ki= 0.7 µM). Inhibits forskolin-induced cAMP accumulation, increases binding of GTPγS to cerebellar membranes, inhibits electrically-evoked contractions of mouse vas deferens and production of hypothermia in mice. Active in vivo.
Product Details
| Formula: | C23H37NO |
| |
| MW: | 343.6 |
| |
| CAS: | 229021-64-1 |
| |
| Purity: | ≥98% (TLC) |
| |
| Appearance: | Pale yellow oil. |
| |
| Solubility: | Soluble in DMSO (25mg/ml), 100% ethanol (25mg/ml) or dimethyl formamide. 1mg/ml soluble in a 1:1 solution of ethanol:PBS (pH 7.2) (dilute the ethanol solution with PBS). |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Handling: | Protect from air. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice: H. Shafaroodi, et al.; Neuropharmacology
47, 390 (2004),
Abstract;
Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors: A. Franklin & N. Stella; Eur. J. Pharmacol.
474, 195 (2003),
Abstract;
Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1): C.J. Hillard, et al.; J. Pharmacol. Exp. Ther.
289, 1427 (1999),
Abstract;
